CSIMarket Company Name, Ticker, Suppliers, else..
 
Better Therapeutics Inc   (NASDAQ: BTTX)
Other Ticker:  
 
 
Price: $0.0004 $0.00 300.000%
Day's High: $0.0004 Week Perf: 100 %
Day's Low: $ 0.00 30 Day Perf: 100 %
Volume (M): 2 52 Wk High: $ 0.03
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 39
 Employees 55
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 1

Better Therapeutics Inc
Better Therapeutics Inc. is a digital therapeutics company that aims to provide evidence-based treatment for chronic diseases. The company develops and offers software platform and associated therapies to help patients manage and improve their health. They utilize cognitive and behavioral approaches to design personalized solutions for conditions such as Type 2 diabetes, hypertension, and other related ailments. By combining technology with clinical expertise, Better Therapeutics Inc. provides accessible and effective treatments to patients, thereby improving their overall well-being and reducing healthcare costs.


   Company Address: 548 Market St. #49404 San Francisco 94104 CA
   Company Phone Number: 887-2311   Stock Exchange / Ticker: NASDAQ BTTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
EUDA        8.55% 
TLSI   -2.34%    
AMGN   -3.04%    
CRSP        11.64% 
EDIT        17.39% 
REGN   -3.26%    
• View Complete Report
   



Business Update

Better Therapeutics Seeks Strategic Alternatives and Initiates Delisting from Nasdaq

Published Thu, Mar 14 2024 1:38 PM UTC

:Better Therapeutics, Inc. (NASDAQ: BTTX) has announced its intention to pursue strategic alternatives and initiate the process of delisting from the Nasdaq Stock Market. At a special board meeting held on Wednesday evening, March 13, 2024, the decision was made to terminate employees and explore various options, including assignment for the benefit of creditors as well as...
Contract

Better Therapeutics and American College of Lifestyle Medicine Partner to Elevate Diabetes Management in Underserved Communities

Published Tue, Mar 5 2024 2:25 PM UTC

Better Therapeutics, a leading company in prescription digital therapeutics for managing cardiometabolic diseases, has recently formed a groundbreaking partnership with the American College of Lifestyle Medicine s National Training Initiative. This collaboration aims to enhance diabetes outcomes in underserved communities across the United States, making healthcare more acce...
Product Service News

Unveiling the Future: Better Therapeutics Presents Game-Changing Results at International Diabetes Conference

Published Mon, Mar 4 2024 2:25 PM UTC

Better Therapeutics, a leading developer of prescription digital therapeutics (PDTs) for managing cardiometabolic diseases, has recently made significant strides. The company announced the acceptance of a late-breaking abstract showcasing 180-day outcomes data from its AspyreRx pivotal trial. Additionally, Better Therapeutics is participating in the highly acclaimed 17th Int...
Product Service News

Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

Published Tue, Feb 20 2024 2:25 PM UTC

San Francisco-based company Better Therapeutics Inc. (NASDAQ: BTTX), known for its pioneering work in developing prescription digital therapeutics (PDTs) for cardiometabolic diseases, has achieved a significant milestone. The United States Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Better Therapeutics innovative Cognitive Behavioral T...
Contract

Rebate Agreement Fuels Better Therapeutics' Foray into Mainstream Healthcare with its Digital Diabetes Solution AspyreRx

Published Tue, Feb 6 2024 2:43 PM UTC

In a remarkable stride towards the revolutionization of the healthcare industry, Better Therapeutics Inc., a flagbearer in the realm of prescription digital therapeutics (PDTs), has secured a significant rebate agreement with one of the top Pharmacy Benefit Managers (PBMs) in America. This move denotes an all-encompassing embrace of digital therapeutics as a new treatment pa...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com